Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA and Toripalimab in advanced TNBC
NCT06371274Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Oct 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of tretinoin in triple-negative breast cancer (TNBC), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Objective Response Rate at 2 years. Started Oct 2024; status: recruiting.
02
Drugs
tretinoin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06371274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06371274.